Session » (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1219

Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 1210

Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort

10:30AM-12:30PM: Abstract Number: 1214

Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis

10:30AM-12:30PM: Abstract Number: 1209

Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1207

Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1195

Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies

10:30AM-12:30PM: Abstract Number: 1191

Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis

10:30AM-12:30PM: Abstract Number: 1197

Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation

10:30AM-12:30PM: Abstract Number: 1202

High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort

10:30AM-12:30PM: Abstract Number: 1192

Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine

10:30AM-12:30PM: Abstract Number: 1198

Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab

10:30AM-12:30PM: Abstract Number: 1199

Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations

10:30AM-12:30PM: Abstract Number: 1193

Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis

10:30AM-12:30PM: Abstract Number: 1216

Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1200

Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)

10:30AM-12:30PM: Abstract Number: 1208

Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression

10:30AM-12:30PM: Abstract Number: 1206

Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis

10:30AM-12:30PM: Abstract Number: 1211

Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis

10:30AM-12:30PM: Abstract Number: 1220

Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases

10:30AM-12:30PM: Abstract Number: 1196

Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1201

Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1205

Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.

10:30AM-12:30PM: Abstract Number: 1212

Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia

10:30AM-12:30PM: Abstract Number: 1215

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort

10:30AM-12:30PM: Abstract Number: 1194

Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1203

Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series

10:30AM-12:30PM: Abstract Number: 1218

Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients

10:30AM-12:30PM: Abstract Number: 1213

Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)

10:30AM-12:30PM: Abstract Number: 1217

Validation and clincial use of anti-MDA5 test – LIA versus ELISA

10:30AM-12:30PM: Abstract Number: 1204

Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.

« View all sessions from this meeting